Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GI safety of OTC ibuprofen

This article was originally published in The Tan Sheet

Executive Summary

Whitehall-Robins' clinical trial in 234 subjects aged 65 or older indicates that the gastrointestinal safety profile of Advil is similar to placebo, according to results presented at the American College of Gastroenterology annual scientific meeting in Boston on Oct. 12. The subjects were a subset of a larger study involving 1,246 subjects comparing the GI safety profile of two Advil formulations: the new liqui-gel and a film-coated tablet. There were "no significant differences" between the treatment groups and placebo in terms of adverse events including dyspepsia, diarrhea, abdominal pain, nausea and intestinal ulceration, the study by Geraldine Doyle, PhD, et al. found

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088978

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel